603 research outputs found
Interactions of Change in Nutrition After AI on Plasma Metabolites, Steroid Hormone Production, and Uterine Environment
Objective The objective was to evaluate the impact of nutritional changes post artificial insemination (AI) on plasma metabolites, steroid hormones, and uterine environment. Study Description Beef heifers (n = 43) were randomly assigned to two dietary treatment groups (High = 161.5% or Low = 77.5% of maintenance energy) for 14 d after AI (post-AI). Post-AI dietary treatments continued until uteri were flushed for embryo recovery (d 14 post-AI). Blood samples were collected on d -3, 0 (day of AI), 3, 6, 9, 12, and 14 for analysis of plasma glucose, proteins, non-esterified fatty acids (NEFAs), and cholesterol using colorimetric assays. Plasma collected on d 0, 3, 6, 9, 12, and 14 was analyzed for progesterone concentrations by radioimmunoassay. Uterine flushes were analyzed for mineral concentrations of Mg, P, S, K, Ca, Cu, Zn, Se, Mn, Co, B, Cr, and Fe by Inductively Coupled Plasma Mass Spectrometry (ICP-MS). Plasma progesterone, NEFAs, protein, glucose and cholesterol (repeated measures) and uterine mineral concentrations were analyzed using the MIXED procedures in SAS. Plasma NEFA concentrations differed between treatments (P = 0.03) with heifers on the low diet treatment having elevated NEFA concentrations. Plasma NEFA concentrations werenât affected by embryo recovery (P \u3e 0.10), treatment by embryo recovery (P \u3e 0.10), and treatment by embryo recovery by day (P \u3e 0.10). Plasma progesterone, glucose, protein, and cholesterol concentrations were not influenced by treatment (P \u3e 0.10), embryo recovery (P \u3e 0.10), treatment by embryo recovery (P \u3e 0.10), and treatment by embryo recovery by day (P \u3e 0.10). Uterine mineral concentrations were affected by embryo presence for Mg (P = 0.02) and S (P = 0.01) a tendency for Ca (P = 0.08) with decreased concentrations in uterine flushes when an embryo was recovered. A tendency for increased concentration of Mn (P = 0.06) was observed in uterine flushes when an embryo was recovered. Additionally, treatment tended to impact Fe concentrations (P = 0.09), with heifers on the restricted diet having reduced uterine Fe concentrations. In conclusion, changing plane of nutrition post-AI had an effect on NEFA plasma concentrations, but no effect on plasma progesterone, protein, glucose, and cholesterol concentrations. The presence of an embryo however affected uterine mineral concentrations
Recommended from our members
Prevalence of Potentially Inappropriate Medication use in older drivers
Background
Potentially Inappropriate Medication (PIM) use has been studied in a variety of older adult populations across the world. We sought to examine the prevalence and correlates of PIM use in older drivers.
Methods
We applied the American Geriatrics Society 2015 Beers Criteria to baseline data collected from the âbrown-bagâ review of medications for participants of the Longitudinal Research on Aging Drivers (LongROAD) study to examine the prevalence and correlates of PIM use in a geographically diverse, community-dwelling sample of older drivers (n =â2949). Proportions of participants who used one or more PIMs according to the American Geriatrics Society 2015 Beers Criteria, and estimated odds ratios (ORs) and 95% confidence intervals (CIs) of PIM use associated with participant characteristics were calculated.
Results
Overall, 18.5% of the older drivers studied used one or more PIM. The most commonly used therapeutic category of PIM was benzodiazepines (accounting for 16.6% of the total PIMs identified), followed by nonbenzodiazepine hypnotics (15.2%), antidepressants (15.2%), and first-generation antihistamines (10.5%). Compared to older drivers on four or fewer medications, the adjusted ORs of PIM use were 2.43 (95% CI 1.68â3.51) for those on 5â7 medications, 4.19 (95% CI 2.95â5.93) for those on 8â11 medications, and 8.01 (95% CI 5.71â11.23) for those on â„12 medications. Older drivers who were female, white, or living in urban areas were at significantly heightened risk of PIM use.
Conclusion
About one in five older drivers uses PIMs. Commonly used PIMs are medications known to impair driving ability and increase crash risk. Implementation of evidence-based interventions to reduce PIM use in older drivers may confer both health and safety benefits.
Trial registration
Not applicable
Recommended from our members
Prevalence of Potentially Inappropriate Medication use in older drivers
Abstract
Background
Potentially Inappropriate Medication (PIM) use has been studied in a variety of older adult populations across the world. We sought to examine the prevalence and correlates of PIM use in older drivers.
Methods
We applied the American Geriatrics Society 2015 Beers Criteria to baseline data collected from the âbrown-bagâ review of medications for participants of the Longitudinal Research on Aging Drivers (LongROAD) study to examine the prevalence and correlates of PIM use in a geographically diverse, community-dwelling sample of older drivers (n =â2949). Proportions of participants who used one or more PIMs according to the American Geriatrics Society 2015 Beers Criteria, and estimated odds ratios (ORs) and 95% confidence intervals (CIs) of PIM use associated with participant characteristics were calculated.
Results
Overall, 18.5% of the older drivers studied used one or more PIM. The most commonly used therapeutic category of PIM was benzodiazepines (accounting for 16.6% of the total PIMs identified), followed by nonbenzodiazepine hypnotics (15.2%), antidepressants (15.2%), and first-generation antihistamines (10.5%). Compared to older drivers on four or fewer medications, the adjusted ORs of PIM use were 2.43 (95% CI 1.68â3.51) for those on 5â7 medications, 4.19 (95% CI 2.95â5.93) for those on 8â11 medications, and 8.01 (95% CI 5.71â11.23) for those on â„12 medications. Older drivers who were female, white, or living in urban areas were at significantly heightened risk of PIM use.
Conclusion
About one in five older drivers uses PIMs. Commonly used PIMs are medications known to impair driving ability and increase crash risk. Implementation of evidence-based interventions to reduce PIM use in older drivers may confer both health and safety benefits.
Trial registration
Not applicable.https://deepblue.lib.umich.edu/bitstream/2027.42/152209/1/12877_2019_Article_1287.pd
The origin and evolution of the normal Type Ia SN 2018aoz with infant-phase reddening and excess emission
SN~2018aoz is a Type Ia SN with a -band plateau and excess emission in the
infant-phase light curves 1 day after first light, evidencing an
over-density of surface iron-peak elements as shown in our previous study.
Here, we advance the constraints on the nature and origin of SN~2018aoz based
on its evolution until the nebular phase. Near-peak spectroscopic features show
the SN is intermediate between two subtypes of normal Type Ia: Core-Normal and
Broad-Line. The excess emission could have contributions from the radioactive
decay of surface iron-peak elements as well as ejecta interaction with either
the binary companion or a small torus of circumstellar material. Nebular-phase
limits on H and He~I favour a white dwarf companion, consistent with
the small companion size constrained by the low early SN luminosity, while the
absence of [O~I] and He~I disfavours a violent merger of the progenitor. Of the
two main explosion mechanisms proposed to explain the distribution of surface
iron-peak elements in SN~2018aoz, the asymmetric Chandrasekhar-mass explosion
is less consistent with the progenitor constraints and the observed blueshifts
of nebular-phase [Fe~II] and [Ni~II]. The helium-shell double-detonation
explosion is compatible with the observed lack of C spectral features, but
current 1-D models are incompatible with the infant-phase excess emission,
color, and absence of nebular-phase [Ca~II]. Although
the explosion processes of SN~2018aoz still need to be more precisely
understood, the same processes could produce a significant fraction of Type Ia
SNe that appear normal after 1 day.Comment: Submitted for publication in ApJ. 35 pages, 16 figures, 7 table
SN 2022crv: IIb, Or Not IIb: That is the Question
We present optical and near-infrared observations of SN~2022crv, a stripped
envelope supernova in NGC~3054, discovered within 12 hrs of explosion by the
Distance Less Than 40 Mpc Survey. We suggest SN~2022crv is a transitional
object on the continuum between SNe Ib and SNe IIb. A high-velocity hydrogen
feature (20,000 -- 16,000 ) was conspicuous in
SN~2022crv at early phases, and then quickly disappeared around maximum light.
By comparing with hydrodynamic modeling, we find that a hydrogen envelope of
\msun{} can reproduce the behaviour of the hydrogen feature
observed in SN~2022crv. The early light curve of SN~2022crv did not show
envelope cooling emission, implying that SN~2022crv had a compact progenitor
with extremely low amount of hydrogen. The analysis of the nebular spectra
shows that SN~2022crv is consistent with the explosion of a He star with a
final mass of 4.5 -- 5.6 \msun{} that has evolved from a 16 -- 22
\msun{} zero-age main sequence star in a binary system with about 1.0 -- 1.7
\msun{} of oxygen finally synthesized in the core. The high metallicity at the
supernova site indicates that the progenitor experienced a strong stellar wind
mass loss. In order to retain a small amount of residual hydrogen at such a
high metallicity, the initial orbital separation of the binary system is likely
larger than 1000~. The near-infrared spectra of SN~2022crv
show a unique absorption feature on the blue side of He I line at
1.005~m. This is the first time that such a feature has been
observed in a Type Ib/IIb, and could be due to \ion{Sr}{2}. Further detailed
modelling on SN~2022crv can shed light on the progenitor and the origin of the
mysterious absorption feature in the near infrared.Comment: 33 pages, 23 figures, submitted to Ap
Strong Carbon Features and a Red Early Color in the Underluminous Type Ia SN 2022xkq
We present optical, infrared, ultraviolet, and radio observations of SN
2022xkq, an underluminous fast-declining type Ia supernova (SN Ia) in NGC 1784
( Mpc), from to 180 days after explosion. The
high-cadence observations of SN 2022xkq, a photometrically transitional and
spectroscopically 91bg-like SN Ia, cover the first days and weeks following
explosion which are critical to distinguishing between explosion scenarios. The
early light curve of SN 2022xkq has a red early color and exhibits a flux
excess which is more prominent in redder bands; this is the first time such a
feature has been seen in a transitional/91bg-like SN Ia. We also present 92
optical and 19 near-infrared (NIR) spectra, beginning 0.4 days after explosion
in the optical and 2.6 days after explosion in the NIR. SN 2022xkq exhibits a
long-lived C I 1.0693 m feature which persists until 5 days post-maximum.
We also detect C II 6580 in the pre-maximum optical spectra. These
lines are evidence for unburnt carbon that is difficult to reconcile with the
double detonation of a sub-Chandrasekhar mass white dwarf. No existing
explosion model can fully explain the photometric and spectroscopic dataset of
SN 2022xkq, but the considerable breadth of the observations is ideal for
furthering our understanding of the processes which produce faint SNe Ia.Comment: 38 pages, 16 figures, accepted for publication in ApJ, the figure 15
input models and synthetic spectra are now available at
https://zenodo.org/record/837925
Oral abstracts 3: RA Treatment and outcomesO13.âValidation of jadas in all subtypes of juvenile idiopathic arthritis in a clinical setting
Background: Juvenile Arthritis Disease Activity Score (JADAS) is a 4 variable composite disease activity (DA) score for JIA (including active 10, 27 or 71 joint count (AJC), physician global (PGA), parent/child global (PGE) and ESR). The validity of JADAS for all ILAR subtypes in the routine clinical setting is unknown. We investigated the construct validity of JADAS in the clinical setting in all subtypes of JIA through application to a prospective inception cohort of UK children presenting with new onset inflammatory arthritis. Methods: JADAS 10, 27 and 71 were determined for all children in the Childhood Arthritis Prospective Study (CAPS) with complete data available at baseline. Correlation of JADAS 10, 27 and 71 with single DA markers was determined for all subtypes. All correlations were calculated using Spearman's rank statistic. Results: 262/1238 visits had sufficient data for calculation of JADAS (1028 (83%) AJC, 744 (60%) PGA, 843 (68%) PGE and 459 (37%) ESR). Median age at disease onset was 6.0 years (IQR 2.6-10.4) and 64% were female. Correlation between JADAS 10, 27 and 71 approached 1 for all subtypes. Median JADAS 71 was 5.3 (IQR 2.2-10.1) with a significant difference between median JADAS scores between subtypes (p < 0.01). Correlation of JADAS 71 with each single marker of DA was moderate to high in the total cohort (see Table 1). Overall, correlation with AJC, PGA and PGE was moderate to high and correlation with ESR, limited JC, parental pain and CHAQ was low to moderate in the individual subtypes. Correlation coefficients in the extended oligoarticular, rheumatoid factor negative and enthesitis related subtypes were interpreted with caution in view of low numbers. Conclusions: This study adds to the body of evidence supporting the construct validity of JADAS. JADAS correlates with other measures of DA in all ILAR subtypes in the routine clinical setting. Given the high frequency of missing ESR data, it would be useful to assess the validity of JADAS without inclusion of the ESR. Disclosure statement: All authors have declared no conflicts of interest. Table 1Spearman's correlation between JADAS 71 and single markers DA by ILAR subtype ILAR Subtype Systemic onset JIA Persistent oligo JIA Extended oligo JIA Rheumatoid factor neg JIA Rheumatoid factor pos JIA Enthesitis related JIA Psoriatic JIA Undifferentiated JIA Unknown subtype Total cohort Number of children 23 111 12 57 7 9 19 7 17 262 AJC 0.54 0.67 0.53 0.75 0.53 0.34 0.59 0.81 0.37 0.59 PGA 0.63 0.69 0.25 0.73 0.14 0.05 0.50 0.83 0.56 0.64 PGE 0.51 0.68 0.83 0.61 0.41 0.69 0.71 0.9 0.48 0.61 ESR 0.28 0.31 0.35 0.4 0.6 0.85 0.43 0.7 0.5 0.53 Limited 71 JC 0.29 0.51 0.23 0.37 0.14 -0.12 0.4 0.81 0.45 0.41 Parental pain 0.23 0.62 0.03 0.57 0.41 0.69 0.7 0.79 0.42 0.53 Childhood health assessment questionnaire 0.25 0.57 -0.07 0.36 -0.47 0.84 0.37 0.8 0.66 0.4
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in single populations, with the majority of reports focused on White in Europe and North America. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on 18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained from 69 centers in 49 countries on six continents. This study comprehensively describes the characteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated) mutations identified in the CIMBA database. We observed substantial variation in mutation type and frequency by geographical region and race/ethnicity. In addition to known founder mutations, mutations of relatively high frequency were identified in specific racial/ethnic or geographic groups that may reflect founder mutations and which could be used in targeted (panel) first pass genotyping for specific populations. Knowledge of the population-specific mutational spectrum in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more broad-based oncogenetic testing in some populations
Finishing the euchromatic sequence of the human genome
The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers âŒ99% of the euchromatic genome and is accurate to an error rate of âŒ1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead
- âŠ